Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR EXT
2023-506210-40-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, open-label, single-arm trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event and Number of participants who discontinue study treatment due to an adverse event. Started Mar 2024; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-506210-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506210-40-00.